“Asthma Devices Market Business Opportunity to 2027 – Top Companies Aristopharma, Boehringer Ingelheim, SRS PHARMACEUTICALS - KSU | The Sentinel Newspaper” plus 1 more
“Asthma Devices Market Business Opportunity to 2027 – Top Companies Aristopharma, Boehringer Ingelheim, SRS PHARMACEUTICALS - KSU | The Sentinel Newspaper” plus 1 more |
| Posted: 19 Jan 2021 11:31 PM PST  The Insight Partners adds "Asthma Devices Market Forecast to 2027 – COVID-19 Impact and Global Analysis" to its store providing analysis of the current and future market competition in the market. Insightful review of the key industry drivers, opportunities, barriers and challenges. Each trend is independently researched to provide qualitative analysis of its implications. Asthma is the chronic inflammatory condition of airways and lungs which makes breathing difficult and also triggers severe coughing. The symptoms of asthma are, whistling sound from breathing, wheezing, tightness in chest, difficulty while talking, fatigue etc. Asthma devices are the set of medical devices which delivers medicine directly to the lungs and help to treat the conditions like asthma as well as COPD. Asthma devices include, inhalers, nebulizers, mesh nebulizers, metered dose inhalers. Get Sample PDF Report along with TOC, Table of Figure, Chart @ https://www.theinsightpartners.com/sample/TIPRE00018026/ Competitive Landscape:
The Covid-19 (coronavirus) pandemic is impacting society and the overall economy across the world. The impact of this pandemic is growing day by day as well as affecting the supply chain. The COVID-19 crisis is creating uncertainty in the stock market, massive slowing of supply chain, falling business confidence, and increasing panic among the customer segments. The overall effect of the pandemic is impacting the production process of several industries. This report on 'Asthma Devices Market' provides the analysis on impact on Covid-19 on various business segments and country markets. The reports also showcase market trends and forecast to 2027, factoring the impact of Covid -19 Situation. The researchers have analysed the competitive advantages of those involved in the industries or in the In Asthma Devices industry. While historical years were taken as 2020 – 2027, the base year for the study was 2020. Similarly, the report has given its projection for the year 2020 apart from the outlook for years 2020 – 2027. The objective of the researchers is to find out the sales, value, and status of the In Asthma Devices industry at the international levels. While the status covers the years of 2020 – 2027, the forecast is for the period 2020 – 2027 that will enable market players to not only plan but also execute strategies based on the market needs. The research provides answers to the following key questions:
Purchase Full Copy of This Report @ https://www.theinsightpartners.com/buy/TIPRE00018026/ About Us: The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Life Science, Technology, Healthcare, Manufacturing, Automotive and Defense, Food Beverages, Chemical etc. Contact Us: Call: +1-646-491-9876 Email: sales@theinsightpartners.com |
| Taking Another Look at Nebulizers for Stable COPD - AJMC.com Managed Markets Network Posted: 08 Jan 2021 12:00 AM PST  A recent review revisited the question of whether inhalers and nebulizers have similar effectiveness to manage stable chronic obstructive pulmonary disease (COPD). The last time this issue was analyzed was in 2005; that review, cited over 450 times, concluded that the 2 devices are equivalent when used by patients trained in the devices. However, the review included just 2 studies, had small sample sizes, and only included lung function as an outcome measure, the researchers said. In recent years, evidence has accumulated that inhalers, while convenient and portable, may not be used correctly by a majority of patients, leading to suboptimal medication delivery and compromised health outcomes, according to the authors. For instance, some patients may not have the cognitive or physical ability to work an inhaler device correctly, the authors noted. Their current review, published in Pulmonary Therapy, analyzed consensus group statements, observational studies, clinical trials, and patient surveys from 1996 to 2018. The consensus group recommendations regarding nebulizer use in maintenance treatment came from 7 groups: the National Association for Medical Direction of Respiratory Care; British Thoracic Society Nebulizer Association of Palliative Care Medicine Project Group; European Respiratory Society (ERS) ERS/ISAM Task Force; American Thoracic Society (ATS)/ERS Statement on Research Questions in COPD; Indian National Allergy Asthma Bronchitis Institute and Chest Research Foundation; and the Global Initiative on Chronic Obstructive Lung Disease (GOLD). Citing cost, convenience, portability of treatment, and other issues, the first 6 groups preferred the use of inhalers. From its first report in 2001 until its 2010 report, GOLD also preferred inhalers; however, in 2010, GOLD made its first statement indicating support for nebulizers under certain conditions. In its last 4 reports, GOLD has not made any recommendation for a device one way or another, the authors noted. The review also looked at 4 patient surveys. One found that 75% of patients reported better symptom relief with nebulizers than inhalers; a second showed that 80% of patients and caregivers favored a nebulizer over an inhaler; a third showed that 54% of patients preferred nebulizers over other inhalation devices; and a fourth found most had no preference, although patients with more severe COPD preferred a nebulizer. When it comes to randomized clinical trials comparing nebulizers and inhalers, there is a paucity of high-quality studies, the authors said. In addition, the studies that have been conducted included patient training that is not typical in a real-world setting, and did not include outcomes such as quality of life. They did note 1 observational study that compared inhalers to nebulizers regarding hospital readmissions for acute exacerbations of COPD. The retrospective analysis of patients hospitalized with AECOPD and then readmitted found that all-cause and COPD 30- and 90-day readmission rates were significantly lower for those discharged with a nebulizer compared with a dry powder inhaler, even though patients given nebulizers were older and worse lung function. The authors argued that past research that has discouraged recommendations for nebulizers in stable COPD has been weak and may ignore potential patient preferences for nebulizers despite the challenges associated with them. "We recommend well-designed comparative efficacy and safety trials with LABA/LAMA combinations, with or without ICS, administered by inhalers versus nebulizers to evaluate the role of nebulizers for maintenance therapy in patients with stable COPD," the authors concluded. Reference Terry PD, Dhand R. Maintenance therapy with nebulizers in patients with stable COPD: Need for reevaluation. Pulm Ther. 2020;6(2):177-192. doi: 10.1007/s41030-020-00120-x |
| You are subscribed to email updates from "asthma,asthma nebulizer,asthma treatment" - Google News. To stop receiving these emails, you may unsubscribe now. | Email delivery powered by Google |
| Google, 1600 Amphitheatre Parkway, Mountain View, CA 94043, United States | |
Comments
Post a Comment